Public filings / BCRX on Yahoo Finance (opens in a new tab)
BCRX: insider buying, 13F holders, analyst moves
Biocryst Pharmaceuticals Inc - US
A summary of public filings about Biocryst Pharmaceuticals Inc - US. For the latest insider history, price chart, analyst changes and activist filings, open the live lookup.
SEC Form 13F · Q2 2026
4 of our 100 managers hold BCRX
Combined reported value $414.3M; 1 sold out since Q1 2026.
Holders among our 100 managers: 5 in Q3 2023, 4 in Q2 2026.
| Manager | Value | % of portfolio | Change vs Q1 2026 |
|---|---|---|---|
| RA Capital | $158.3M | 1.38% | Unchanged |
| Deerfield Company | $151.0M | 1.57% | Unchanged |
| Perceptive Advisors | $103.1M | 1.60% | Added |
| Tudor Investment | $2.0M | 0.01% | New |
Important information
Facts from public SEC filings, shown for information only. Not a recommendation. Not individualized investment advice. Gulfstream Capital and its clients may hold positions in securities shown.